Table 2.
Clinical features of the participants who contributed synovial fluid
| Characteristics | RA | OA |
|---|---|---|
| Number of participants | 30 | 30 |
| Sex, male/female | 6/24 | 6/24 |
| Age, mean (range) | 63.1 (32 to 88) | 75.3 (67 to 89) |
| Disease duration (y), mean (range) | 13.0 (0.5 to 50) | NA |
| Positive anti-CCP antibody, n (%) | 10 (83.3%)¶ | NA |
| ESR (mm), mean (range) | 49.6 (4 to 116) | NA |
| CRP (mg/dl), mean (range) | 3.1 (0 to 13.9) | NA |
| MMP3 (ng/ml), mean (range) | 362.7 (43.2 to 800) | NA |
| DAS28, mean (range) | 4.9 (2.2 to 7.1) | NA |
| SJC, mean (range) | 4.9 (0 to 17) | NA |
| TJC, mean (range) | 5.1 (0 to 27) | NA |
| VAS | 52.1 (10 to 95) | NA |
| Steinbrocker Stage, n | I: 3, II: 3, III: 5, IV: 19 | NA |
| Steinbrocker Class, n | I: 1, II: 22, III: 7, IV: 0 | NA |
| Kellgren/Lawrence grade, n | NA | I: 0, II: 0, III: 11, IV: 19 |
| Medication, n (%) | ||
| Prednisolone | 20 (67%) | NA |
| Methotrexate | 15 (50%) | NA |
| Infliximab | 3 (10%) | NA |
| Eternercept | 1 (3.3%) | NA |
| Tocilizumab | 0 (0%) | NA |
| Tacrolimus | 2 (6.7%) | NA |
| Salazosulfapyridine | 8 (27%) | NA |
| Bucillamine | 6 (20%) | NA |
| Mizoribine | 1 (3.3%) | NA |
| Gold | 2 (6.7%) | NA |
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; MMP-3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count score; TJC, tender joint count; VAS, visual analogue scale of general health.
¶anti-CCP antibodies of 10 patients were positive among 12 patients examined.